Specific inhibition of ADP‐induced platelet aggregation by clopidogrel in vitro
- 29 January 1999
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 126 (2) , 415-420
- https://doi.org/10.1038/sj.bjp.0702276
Abstract
The thienopyridine clopidogrel is a specific inhibitor of ADP‐induced platelet aggregation ex vivo. No direct effects of clopidogrel (100 μM) on platelet aggregation in vitro have been described so far. Possible in vitro antiaggregatory effects (turbidimetry) of clopidogrel were studied in human platelet‐rich plasma and in washed platelets. Incubation of platelet‐rich plasma with clopidogrel (100 μM) for up to 8 h did not result in any inhibition of ADP (6 μM)‐induced platelet aggregation. Incubation of washed platelets with clopidogrel resulted in a time‐ (maximum effects after 30 min) and concentration‐dependent (IC50 1.9±0.3 μM) inhibition of ADP (6 μM)‐induced platelet aggregation. Clopidogrel (30 μM) did not inhibit collagen (2.5 μg ml−1)‐, U46619 (1 μM)‐ or thrombin (0.1 u ml−1)‐induced platelet aggregation. The inhibition of ADP‐induced aggregation by clopidogrel (30 μM) was insurmountable indicating a non‐equilibrium antagonism of ADP actions. The R enantiomer SR 25989 C (30 μM) was significantly less active than clopidogrel (30 μM) in inhibiting platelet aggregation (32±5 % vs 70±1 % inhibition, Pn=5). In washed platelets, clopidogrel (30 μM) did not significantly reverse the inhibition of prostaglandin E1 (1 μM)‐induced platelet cyclic AMP formation by ADP (6 μM). The antiaggregatory effects of clopidogrel were unchanged when the compound was removed from the platelet suspension. However, platelet inhibition by clopidogrel was completely abolished when albumin (350 mg ml−1) was present in the test buffer. It is concluded that clopidogrel specifically inhibits ADP‐induced aggregation of washed platelets in vitro without hepatic bioactivation. Inhibition of ADP‐induced platelet aggregation by clopidogrel in vitro occurs in the absence of measurable effects on the reversal of PGE1‐stimulated cyclic AMP by ADP. British Journal of Pharmacology (1999) 126, 415–420; doi:10.1038/sj.bjp.0702276Keywords
This publication has 30 references indexed in Scilit:
- Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrelVascular Medicine, 1998
- Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptorsEuropean Journal of Pharmacology, 1998
- ClopidogrelDrugs, 1997
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptorsBritish Journal of Haematology, 1995
- Clopidogrel and antiplatelet therapyExpert Opinion on Investigational Drugs, 1994
- Direct inhibition of platelet function by organic nitrates via nitric oxide formationEuropean Journal of Pharmacology: Molecular Pharmacology, 1993
- Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADPThrombosis Research, 1987
- Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.Journal of Clinical Investigation, 1985